InnoCore has two patented sustained release technologies which serve as a platform for obtaining advanced long-acting injectable (LAI) formulations of pharmaceutical ingredients. The SynBiosys® and InGell® polymers are biodegradable and bioresorbable in which APIs can be entrapped. The long acting release mechanism of drugs with SynBiosys® microspheres are based upon diffusion whereas the InGell® gels erodes completely via surface erosion. Optionally, PLGA could be used as a drug carrier in microspheres although with limited patent protection.
SynBiosys®
Key features and benefits:
- Suitable for a large variety of compounds, including proteins
- Scalable technology
- Easily adjustable to specific requirements by controlling polymer composition and process conditions
- Well-known, clinically proven safe microspheres
- Full control over physico-chemical and degradation characteristics
- Biodegradable technology
- No accumulation of acidic degradation products
- Drug integrity and bioactivity is preserved by low temperature processing
- Absolute control over particle size
- Patented technology
- High encapsulation efficiency (on average higher than 80%)
InGell®
Key features and benefits:
- Biocompatible polymers safely disappear at the same rate as the release of the drug
- Technology is suitable for a variety of compounds, such as peptides and small molecules
- Drug delivery at even the most sensitive tissue sites
- Injectable through up to 31G needles
- Stabilization of sensitive compounds, e.g. excellent maintenance of bio-activity of peptides
- Simple and mild formulation in aqueous solutions
- Highest loading capacity of all injectable gel technologies (up to 25%)
- Sustained and localized release for days, weeks to months with limited or no burst
- Patented technology
- Soft gels with sufficient strength
PLGA
Key features and benefits:
- Biocompatibility
- Tailored biodegradation rate (small molecules only)
- Approval for clinical use in humans by the U.S. Food and Drug Administration (FDA)
